Comparison of Efficacy of Pitavastatin and Colestimide in Japanese Patients with Diabetes Mellitus Complicated by Hyperlipidemia and Metabolic Syndrome

Abstract

The present study was undertaken to compare the efficacy of pitavastatin and colestimide in patients with diabetes mellitus complicated by hyperlipidemia and metabolic syndrome. 48 diabetic patients with metabolic syndrome were randomly assigned to a pitavastatin group or colestimide group. The clinical parameters, serum lipids, fasting (FPG) and postprandial plasma glucose(PPG), HOMA-IR, hemoglobin A1c(HbA1c), hs-CRP and urinary albumin were measured before/after 24-week administration. Treatment with pitavastatin reduced LDL-C and TG, while that with colestimide significantly reduced waist circumference, BMI, LDL-C, HbA1c, FPG, PPG, HOMA-R , hs-CRP and urinary albumin. Percent improvement in LDL-C was greater in the pitavastatin group than in the colestimide group. Colestimide appeared to be useful in the management of Japanese patients with diabetes mellitus complicated by metabolic syndrome, since it alleviates obesity and insulin resistance in addition to exhibiting lipid profile-improving effects, and can thus improve markers of atherosclerosis.

Key words

atherosclerosis - LDL-cholesterol (LDL-C) - high-sensitivity CRP (hs-CRP)

References

• 1 Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition.  Lancet. 2005;  366 1059-1062
• 2 Ast M, Frishman WH. Bile acid sequestrants.  J Clin Pharm. 1990;  30 99-106
• 3 Devaraj S, Autret B, Jialal I. Effect of Colesevelam Hydrochloride(WelChol) on Biomarkers of Inflammation in Patients With Mild Hypercholesterolemia.  Am J Cardiol. 2006;  98 641-643
• 4 Examination Committee for Metabolic Syndrome Diagnostic Criteria. . Japanese Metabolic Syndrome Diagnostic Criteria.  J Jpn Soc Intern Med. 2005;  94 (4) 794-809
• 5 Handa N, Matsumoto M, Maeda H. et al . Ultrasonic evaluation of early carotid atherosclerosis.  Stroke. 1990;  21 1567-1572
• 6 Kajiyayama G, Tzazumz S, Yamashita G. et al . Effect of MIC-196 on biliary lipids metabolism in patients with hypercholesterolemia.  Rinsho Iyaku. 1996;  12 1349-1359
• 7 Kawabata Y, Ikegami H, Fujisawa T. et al . Bile-acid binding resin ameliorates glycemic control in patients with type 2 Diabetes.  Diabetes. 2006;  55 (supple 1) 120A
• 8 Kobayashi M, Ikegami H, Fujisawa T. et al . Prevention and treatment of obesity, insulin resistance and diabetes by bile acid-binding resin.  Diabetes. 2007;  56 239-247
• 9 Levy RI, Brensike JF, Epstein SE. et al . The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of the NHLBI Type II Coronary Intervention study.  Circulation. 1984;  69 325-337
• 10 Lipid Research Clinics Program. . The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.  JAMA. 1984;  251 351-364
• 11 Nakata M, Nagasaka S, Kusaka L. et al . Effects of statins on the adipocyte maturation and expression of glucose transporter 4)SCL2A4): implications in glycaemic control.  Diabetologia. 2006;  49 1881-1892
• 12 Naveed S, David P, Heather MM. et al . Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials.  Lancet. 2010;  375 735-742
• 13 Osaki F, Ikeda Y, Hiroshue T. et al . Effects of stains on glucose metabolism.  Japanese Journal of Clinical & Experimental Medicine. 2005;  82 359-363
• 14 Research and Study Committee for Diagnostic Criteria of Diabetes Mellitus. . Report of the Committee of Japan Diabetes Society on the Classification and Diagnostic Criteria of Diabetes Mellitus.  Journal of the Japan Diabetic Society. 2010;  53 450-467
• 15 Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention.  Circulation. 2003;  107 363-369
• 16 Sabatine MS, Wiviott SD, Morrow DA. et al . High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy.  Circulation. 2004;  110 (Suppl III) III–834. (Abstract)
• 17 Sever PS, Poulter NR, Dahlôf B. et al . For the ASCOT Investigators: Reduction in Cardiovascular Events With Atorvastatin in 2 532 Patients With Type 2 Diabetes.  Diabetes Care. 2005;  28 (5) 1151
• 18 Stayrook KR, Bramlett KS, Savkur RS. et al . Regulation of carbohydrate metabolism by the farnesoid x receptor.  Endocrinology. 2005;  146 984-991
• 19 Suzuki T, Obe K, Futami S. et al . Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose.  Nippon Med Sch. 2006;  73 277-284
• 20 Takebayashi K, Suetsugu M, Matsumoto S. et al . Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia.  South Med J. 2009;  102 361-368
• 21 Urizar NL, Liverman AB, Dodds DT. et al . Anatural product that lowers cholesterol as an antagonist ligand for FXR.  Science. 2002;  296 1703-1706
• 22 Watanabe M, Houten SM, Mataki C. et al . Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.  Nature. 2006;  439 484-489
• 23 Yamakawa T, Takano T, Utsunomiya H. et al . Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia.  Endocr J. 2007;  54 (1) 53-58

Correspondence